ARDX FINANCIAL STATEMENTS

Ardelyx Inc — balance sheet, income statement and cash flow trends

ARDXArdelyx Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue427.7 M $+18.2%

Gross Profit393.2 M $+29.0%

Operating Income-37.4 M $—

EBITDA-25.5 M $—

Net Income-58.1 M $—

Peer Comparison· Biotechnology

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
ARDX	18.2%	91.9%	-6.0%	-13.6%
MSB	410.4%	-32.0%	-76.6%	-115.3%
TLX	56.3%	50.8%	3.0%	-0.9%
CSL	4.8%	48.6%	32.8%	9.2%
RTALB	24.0%	35.1%	9.0%	136.3%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
ARDX	18.2%	91.9%	-6.0%	-13.6%
OLMA	-100.0%	—	—	—
WVE	-31.6%	93.8%	-243.2%	-255.7%
KALV	—	92.2%	-52.4%	-78.6%
ORIC	-100.0%	—	—	—
MNKD	21.2%	76.0%	7.6%	-6.6%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity148.6 M $29%
Current Liabilities109.6 M $22%
Long-term Liabilities246.3 M $49%

Key Figures

YoY change

Total Assets504.5 M $+23.0%

Total Liabilities355.9 M $+34.5%

Total Equity148.6 M $+2.0%

Cash & ST Investments238.1 M $+11.3%

Total Debt208.3 M $+34.3%

Net Debt177.1 M $+42.4%

Peer Comparison· Biotechnology

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
ARDX	3.49	140.1%	1.17	29.5%
MSB	—	—	—	—
TLX	1.43	112.3%	13.13	35.1%
CSL	2.57	67.4%	2.22	49.2%
RTALB	1.21	1.2%	0.90	84.9%
Industry median	5.90	10.9%	1.15	70.0%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
ARDX	3.49	140.1%	1.17	29.5%
OLMA	10.88	0.2%	2.73	90.5%
WVE	11.26	3.1%	3.03	87.7%
KALV	5.58	-10,483.5%	0.21	-0.8%
ORIC	16.33	0.8%	2.08	95.1%
MNKD	1.87	-737.7%	10.99	-8.0%
Industry median	5.90	10.9%	1.15	70.0%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow-36.3 M $—

Capital Expenditures1.2 M $+4.2%

Free Cash Flow-37.5 M $—

Dividends Paid——

Peer Comparison· Biotechnology

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
ARDX	-8.5%	-8.8%	0.3%	62.5%
MSB	-87.7%	-90.0%	2.3%	76.1%
TLX	-2.2%	-6.3%	4.1%	243.1%
CSL	24.0%	20.3%	3.7%	261.5%
RTALB	58.5%	88.6%	10.8%	42.9%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
ARDX	-8.5%	-8.8%	0.3%	62.5%
OLMA	—	—	—	80.3%
WVE	-254.0%	-255.4%	1.4%	99.3%
KALV	-26.6%	-26.9%	0.5%	33.8%
ORIC	—	—	—	82.0%
MNKD	5.2%	3.5%	1.7%	-78.8%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on ARDX

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.